Calliditas Therapeutics AB (publ)
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Renee Aguiar-Lucander
- Full Time Employees
- 222
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Kungsbron 1, D5 Stockholm Sweden 111 22
- IPO Date
- Jun 5, 2020
- CIK
- 0001795579
- Website
- calliditas.se
- Similar Companies
- Business
- Calliditas Therapeutics AB (publ) is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing pharmaceutical products for the treatment of orphan indications, primarily renal and hepatic diseases. The company manufactures and markets Nefecon, an oral formulation of budesonide designed as an immunosuppressant for immunoglobulin A nephropathy (IgAN), a rare autoimmune renal disease. It also develops Setanaxib, a NOX inhibitor in Phase 2b/3 clinical trials targeting primary biliary cholangitis and other conditions including idiopathic pulmonary fibrosis and certain cancers, alongside Budenofalk 3 mg oral capsules for autoimmune hepatitis. Calliditas operates mainly in Europe and the United States, serving patients with significant unmet medical needs in niche drug markets. Founded in 2004 and headquartered in Stockholm, Sweden, the company leverages its interdisciplinary expertise in pharmaceutical product development for orphan diseases. Recent major company developments include the acquisition by Asahi Kasei Corporation, which launched a tender offer in May 2024 and by early September 2024 had acquired over 90 percent ownership of Calliditas shares, leading to the company’s application for delisting from Nasdaq Stockholm. Additionally, the European Commission granted full approval for Kinpeygo, the brand name for Nefecon, for the treatment of IgA nephropathy, further solidifying its market position. Calliditas also recently launched IgAN Connect, an online platform to support patients and healthcare professionals. These strategic shifts underscore the company’s expansion and enhanced commercialization capabilities in rare renal diseases. Calliditas maintains a strong pipeline with ongoing clinical trials and focuses on developing innovative therapies that address significant unmet medical needs in specialized treatment areas, continuing its commitment to patients with rare renal and hepatic disorders.
Financial Survey: MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
Analyzing Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & Palatin Technologies (PINK:PTNT) Critical Analysis
Head-To-Head Review: AngioSoma (OTCMKTS:SOAN) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
Evofem Biosciences (NASDAQ:EVFM) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Head-To-Head Survey
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript
Calliditas Interim Report January to June 2024
Number of shares and votes in Calliditas Therapeutics
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders
STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALT
STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas provides setanaxib patent update
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger and Expiring Tender Offer - AKLI and CALT